In the past five years, multiple structurally and functionally distinct androgen receptor (AR)
splice variants have been decoded and characterized. The mature transcripts for the …

The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical
landscape of prostate cancer treatment. Both drugs were designed to further suppress …

Recurrent, metastatic prostate cancer continues to be a leading cause of cancer-death in
men. The androgen receptor (AR) is a modular, ligand-inducible transcription factor that …

Long non-coding RNAs (lncRNAs) have been gaining importance in the field of cancer
research in recent years. PRNCR1 (prostate cancer-associated non-coding RNA1) is a 12.7 …

Finasteride is an inhibitor of 5-α-reductase used against male androgenetic alopecia (AGA).
Reported side effects of finasteride comprise sexual dysfunction including erectile …

Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men and has
an extremely heterogeneous clinical behaviour. The vast majority of PCas are hormonally …

Aims: Our study aimed to evaluate the diagnostic and prognostic values of microRNA-21
(miR-21) expression levels in peripheral blood mononuclear cells (PBMCs) for prostate …

The present study aimed to investigate whether microRNA (miR)‑185 downregulated
androgen receptor expression in the LNCaP prostate carcinoma cell line. Human prostate …

The standard of care for patients who suffer from non-organ confined prostate cancer (CaP)
is androgen deprivation therapy (ADT). ADT exploits the reliance of CaP cells on androgen …

INTRODUCTION The Prouts Neck Meetings on Prostate Cancer began in 1985 through the
efforts of the Organ Systems Branch of the National Cancer Institute to stimulate new …